Landmark Pegasus Inc.
Landmark Pegasus Inc. publicly describes itself as a corporate finance advisory and strategy consulting firm specializing in life sciences and healthcare. Its stated services include buy-side and sell-side M&A, divestitures, recapitalizations, valuations, capital raising, consulting, licensing, joint ventures, and strategic support.
What stands out about Landmark Pegasus Inc.
Landmark Pegasus Inc. offers life-sciences and healthcare advisory services across M&A, capital raising, valuation, strategy, and related corporate finance matters. Its public materials identify domestic and international work and historical transaction examples, but do not publish quantitative client-screening thresholds, detailed dates or values for representative transactions, or universal fee terms.[1][2][4][5][6][7][8]
What does Landmark Pegasus Inc. do?
Landmark Pegasus Inc. identifies itself as a corporate finance advisory and strategy consulting firm specializing in the life-sciences and healthcare industries. Its official site identifies the firm as an affiliate of Landmark Financial Corporation, which it states was established in 1983 to provide corporate finance advisory services to life-sciences companies.
The official contact page lists an address in Jupiter, Florida and identifies John Moroney as President. Florida’s Division of Corporations lists LANDMARK PEGASUS INC as an active Florida profit corporation.[1][2][3]
Publicly stated services include corporate strategy, business development, finance, and operational leadership. The firm also describes business-plan development, economic and market analysis, strategic planning, corporate guidance, interim management, and introductions to banks and funds.
Its stated transaction and corporate finance services include capital raising, licensing and joint ventures, leveraged buyouts, mergers and acquisitions, turnarounds, divestitures, recapitalizations, financial valuations, and post-acquisition integrations.[1][4][5][6]
Owners comparing advisory firms can also review Auxo’s M&A advisor vs. business broker vs. investment bank comparison, advisor-selection guide, and sell-side advisor evaluation framework.
What should a business owner evaluate before hiring Landmark Pegasus Inc.?
For an owner evaluating a potential sale advisory engagement, Landmark Pegasus publicly describes sell-side M&A, valuation, recapitalization, capital-raising, licensing, and strategic-support services focused on life sciences and healthcare. Its public materials also describe domestic and international transaction experience and assistance with U.S. market entry for international pharmaceutical companies.
An owner should request current healthcare and life-sciences sell-side references, including dates, roles, buyer types, and seller references; clarify any client-size or transaction-size parameters; and obtain complete fee, exclusivity, tail, termination, and conflict terms. If securities activities are involved, the owner should clarify which entity will perform those activities and whether a separately registered intermediary will be engaged.[4][6]
What recent healthcare or life-sciences sell-side transactions has Landmark Pegasus completed, and can it provide dates, transaction roles, buyer types, and seller references
What minimum client-size or transaction-size thresholds, if any, apply to a potential engagement
How are fees calculated, including retainers, success fees, expenses, tail provisions, and termination rights
What size transactions and clients does Landmark Pegasus Inc. focus on?
Landmark Pegasus focuses on life-science industries including pharmaceuticals, nutritionals, medical foods, active pharmaceutical ingredients, medical devices, and diagnostics. Its public client materials also reference healthcare services and related healthcare businesses.[1]
The leadership page describes historical advisory work involving IPOs for Par Pharmaceutical, Alfin Fragrances, and Physicians Computer Network, as well as advice to Columbia Laboratories on its IPO and first product acquisition.
It also describes work involving the restructuring and financing of Carrington Laboratories and MacroChem Laboratories, Copley Pharmaceutical’s restructuring and private placement, and advice on F. Faulding & Co.’s acquisition of Solvay’s Purepac division.
The official leadership page provides these historical examples but does not identify transaction dates, transaction values, buyer identities, or seller identities for them.[8]
The firm’s M&A offering covers buy-side and sell-side transactions, divestitures, recapitalizations, financial valuations, and post-acquisition integrations. Its public materials also identify capital raising, licensing, joint ventures, leveraged buyouts, and turnarounds as areas of service.
Landmark Pegasus states that it has counseled over 50 foreign and domestic companies in M&A transactions and has particular expertise assisting international pharmaceutical companies with entry into the U.S. market.[4][6]
What does Landmark Pegasus Inc. publicly disclose about fees, process and engagement terms?
The official M&A page does not state minimum revenue, EBITDA, enterprise-value, transaction-size, or other quantitative client-screening thresholds. The official homepage describes the firm as serving established and emerging-growth companies but does not publish a universal quantitative client-size criterion.
The official leadership page provides historical transaction examples but does not identify transaction dates, transaction values, buyer identities, or seller identities. The official capital-raising page does not disclose a universal fee schedule, success-fee percentage, minimum fee, tail period, termination schedule, or transaction-specific compensation terms.
The official client page provides a selected client list and states that the listed companies are organizations the firm currently works with or assisted in the past, but it does not specify the firm’s role or engagement details for each named organization.[1][4][6][7][8]
Landmark Pegasus’s capital-raising page states that the company may not directly sell, offer to sell, or offer to buy any security and does not provide securities brokerage or investment-advising services.
Florida’s Division of Corporations lists LANDMARK PEGASUS INC as an active Florida profit corporation, with John J. Moroney identified as president and registered agent. If a proposed engagement involves securities activities, the firm’s stated role and any separately engaged regulated intermediary should be confirmed directly.[3][6]
The firm’s public materials establish service categories including strategic planning, consulting, capital raising, M&A, valuation, and interim management.[1][4][5][6]
Questions to ask before hiring Landmark Pegasus Inc.
What recent healthcare or life-sciences sell-side transactions has Landmark Pegasus completed, and can it provide dates, transaction roles, buyer types, and seller references?
What minimum client-size or transaction-size thresholds, if any, apply to a potential engagement?
How are fees calculated, including retainers, success fees, expenses, tail provisions, and termination rights?
If a transaction involves securities, which separately registered broker-dealer or investment bank will perform regulated activities?
Will Landmark Pegasus act as an exclusive advisor, and what conflicts or related-party relationships should be disclosed?
Sources & research notes
- Official website / firm overview
- Official website / firm overview
- Structure / regulatory context
- Services / capabilities
- Services / capabilities
- Services / capabilities
- Geography / market coverage
- Transaction / portfolio evidence
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.